nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—Thalidomide—leprosy	0.124	0.148	CbGbCtD
Etoricoxib—PTGS2—Dapsone—leprosy	0.0995	0.118	CbGbCtD
Etoricoxib—CYP2E1—Thalidomide—leprosy	0.0812	0.0964	CbGbCtD
Etoricoxib—CYP2E1—Rifampicin—leprosy	0.0786	0.0933	CbGbCtD
Etoricoxib—CYP2E1—Dapsone—leprosy	0.0649	0.077	CbGbCtD
Etoricoxib—CYP2C19—Thalidomide—leprosy	0.0509	0.0604	CbGbCtD
Etoricoxib—CYP2C19—Rifampicin—leprosy	0.0493	0.0585	CbGbCtD
Etoricoxib—CYP1A2—Thalidomide—leprosy	0.047	0.0557	CbGbCtD
Etoricoxib—CYP1A2—Rifampicin—leprosy	0.0455	0.054	CbGbCtD
Etoricoxib—CYP2C9—Thalidomide—leprosy	0.0423	0.0502	CbGbCtD
Etoricoxib—CYP2C9—Rifampicin—leprosy	0.041	0.0486	CbGbCtD
Etoricoxib—CYP2C19—Dapsone—leprosy	0.0407	0.0483	CbGbCtD
Etoricoxib—CYP2C9—Dapsone—leprosy	0.0338	0.0401	CbGbCtD
Etoricoxib—CYP3A4—Rifampicin—leprosy	0.0238	0.0283	CbGbCtD
Etoricoxib—CYP3A4—Dapsone—leprosy	0.0197	0.0233	CbGbCtD
Etoricoxib—Gingival disorder—Thalidomide—leprosy	0.0106	0.0896	CcSEcCtD
Etoricoxib—Ligament sprain—Dapsone—leprosy	0.00769	0.0653	CcSEcCtD
Etoricoxib—Nephrotic syndrome—Dapsone—leprosy	0.00402	0.0341	CcSEcCtD
Etoricoxib—Rales—Thalidomide—leprosy	0.00242	0.0206	CcSEcCtD
Etoricoxib—Proteinuria—Dapsone—leprosy	0.00221	0.0188	CcSEcCtD
Etoricoxib—Hyporeflexia—Thalidomide—leprosy	0.00219	0.0186	CcSEcCtD
Etoricoxib—Protein urine present—Dapsone—leprosy	0.00218	0.0185	CcSEcCtD
Etoricoxib—Aphthous stomatitis—Thalidomide—leprosy	0.00212	0.018	CcSEcCtD
Etoricoxib—White blood cell count decreased—Thalidomide—leprosy	0.002	0.017	CcSEcCtD
Etoricoxib—Transient ischaemic attack—Thalidomide—leprosy	0.00197	0.0167	CcSEcCtD
Etoricoxib—Platelet count decreased—Thalidomide—leprosy	0.00167	0.0142	CcSEcCtD
Etoricoxib—Toothache—Thalidomide—leprosy	0.00164	0.0139	CcSEcCtD
Etoricoxib—Serum creatinine increased—Thalidomide—leprosy	0.00162	0.0137	CcSEcCtD
Etoricoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—RIPK2—leprosy	0.00159	0.0422	CbGpPWpGaD
Etoricoxib—MAPK14—NOD1/2 Signaling Pathway—CYLD—leprosy	0.00152	0.0405	CbGpPWpGaD
Etoricoxib—MAPK14—activated TAK1 mediates p38 MAPK activation—NOD2—leprosy	0.00144	0.0382	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.00138	0.0367	CbGpPWpGaD
Etoricoxib—Skin ulcer—Thalidomide—leprosy	0.00128	0.0109	CcSEcCtD
Etoricoxib—Muscular weakness—Dapsone—leprosy	0.00124	0.0106	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—LTA—leprosy	0.00124	0.033	CbGpPWpGaD
Etoricoxib—Pancreatitis—Dapsone—leprosy	0.0012	0.0102	CcSEcCtD
Etoricoxib—MAPK14—Parkinsons Disease Pathway—PARK2—leprosy	0.00114	0.0304	CbGpPWpGaD
Etoricoxib—Proteinuria—Thalidomide—leprosy	0.00113	0.00962	CcSEcCtD
Etoricoxib—Protein urine present—Thalidomide—leprosy	0.00112	0.00948	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Dapsone—leprosy	0.00111	0.00945	CcSEcCtD
Etoricoxib—Cellulitis—Thalidomide—leprosy	0.00109	0.00929	CcSEcCtD
Etoricoxib—Herpes simplex—Thalidomide—leprosy	0.00108	0.00917	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Dapsone—leprosy	0.00107	0.00905	CcSEcCtD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—leprosy	0.00104	0.0276	CbGpPWpGaD
Etoricoxib—Sinusitis—Dapsone—leprosy	0.00102	0.00866	CcSEcCtD
Etoricoxib—Blood uric acid increased—Thalidomide—leprosy	0.00101	0.0086	CcSEcCtD
Etoricoxib—Neck pain—Thalidomide—leprosy	0.00101	0.00855	CcSEcCtD
Etoricoxib—Phosphatase alkaline increased—Thalidomide—leprosy	0.000995	0.00845	CcSEcCtD
Etoricoxib—MAPK14—NOD1/2 Signaling Pathway—RIPK2—leprosy	0.000982	0.0261	CbGpPWpGaD
Etoricoxib—Hyperkalaemia—Thalidomide—leprosy	0.000977	0.0083	CcSEcCtD
Etoricoxib—Pharyngitis—Dapsone—leprosy	0.000969	0.00823	CcSEcCtD
Etoricoxib—Blood urea increased—Thalidomide—leprosy	0.000939	0.00798	CcSEcCtD
Etoricoxib—Neuropathy—Thalidomide—leprosy	0.000934	0.00793	CcSEcCtD
Etoricoxib—Tinnitus—Dapsone—leprosy	0.00091	0.00773	CcSEcCtD
Etoricoxib—MAPK14—NOD1/2 Signaling Pathway—NOD2—leprosy	0.000891	0.0236	CbGpPWpGaD
Etoricoxib—Erythema—Dapsone—leprosy	0.00085	0.00721	CcSEcCtD
Etoricoxib—Diabetes mellitus—Thalidomide—leprosy	0.00083	0.00705	CcSEcCtD
Etoricoxib—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00083	0.00705	CcSEcCtD
Etoricoxib—Gastroenteritis—Thalidomide—leprosy	0.000815	0.00692	CcSEcCtD
Etoricoxib—Eczema—Thalidomide—leprosy	0.000804	0.00682	CcSEcCtD
Etoricoxib—Vision blurred—Dapsone—leprosy	0.000801	0.0068	CcSEcCtD
Etoricoxib—Cardiac failure congestive—Thalidomide—leprosy	0.000796	0.00676	CcSEcCtD
Etoricoxib—Injury—Thalidomide—leprosy	0.000786	0.00667	CcSEcCtD
Etoricoxib—Visual disturbance—Thalidomide—leprosy	0.000762	0.00647	CcSEcCtD
Etoricoxib—Atrial fibrillation—Thalidomide—leprosy	0.000762	0.00647	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000744	0.0197	CbGpPWpGaD
Etoricoxib—Cough—Dapsone—leprosy	0.000741	0.0063	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Thalidomide—leprosy	0.000737	0.00626	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000722	0.00613	CcSEcCtD
Etoricoxib—Pain in extremity—Thalidomide—leprosy	0.000722	0.00613	CcSEcCtD
Etoricoxib—Cardiac arrest—Thalidomide—leprosy	0.000687	0.00583	CcSEcCtD
Etoricoxib—Blood creatinine increased—Thalidomide—leprosy	0.000677	0.00575	CcSEcCtD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.00067	0.0178	CbGpPWpGaD
Etoricoxib—MAPK14—CD40/CD40L signaling—CD40LG—leprosy	0.000668	0.0177	CbGpPWpGaD
Etoricoxib—Orthostatic hypotension—Thalidomide—leprosy	0.00066	0.0056	CcSEcCtD
Etoricoxib—Breast disorder—Thalidomide—leprosy	0.000653	0.00554	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.00065	0.00552	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00065	0.00552	CcSEcCtD
Etoricoxib—Cramp muscle—Thalidomide—leprosy	0.00065	0.00552	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000637	0.00541	CcSEcCtD
Etoricoxib—Muscular weakness—Thalidomide—leprosy	0.000637	0.00541	CcSEcCtD
Etoricoxib—Abdominal distension—Thalidomide—leprosy	0.000628	0.00534	CcSEcCtD
Etoricoxib—Insomnia—Dapsone—leprosy	0.000627	0.00533	CcSEcCtD
Etoricoxib—Bronchospasm—Thalidomide—leprosy	0.000614	0.00521	CcSEcCtD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—RIPK2—leprosy	0.000612	0.0162	CbGpPWpGaD
Etoricoxib—Pancreatitis—Thalidomide—leprosy	0.000612	0.0052	CcSEcCtD
Etoricoxib—Angina pectoris—Thalidomide—leprosy	0.000608	0.00516	CcSEcCtD
Etoricoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.000608	0.0161	CbGpPWpGaD
Etoricoxib—Bronchitis—Thalidomide—leprosy	0.0006	0.0051	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000581	0.0154	CbGpPWpGaD
Etoricoxib—Upper respiratory tract infection—Thalidomide—leprosy	0.00058	0.00493	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—RIPK2—leprosy	0.000579	0.0154	CbGpPWpGaD
Etoricoxib—Photosensitivity reaction—Thalidomide—leprosy	0.00057	0.00484	CcSEcCtD
Etoricoxib—Weight increased—Thalidomide—leprosy	0.000568	0.00482	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dapsone—leprosy	0.000567	0.00482	CcSEcCtD
Etoricoxib—Hyperglycaemia—Thalidomide—leprosy	0.000563	0.00478	CcSEcCtD
Etoricoxib—Pneumonia—Thalidomide—leprosy	0.00056	0.00475	CcSEcCtD
Etoricoxib—Infestation—Thalidomide—leprosy	0.000557	0.00473	CcSEcCtD
Etoricoxib—Infestation NOS—Thalidomide—leprosy	0.000557	0.00473	CcSEcCtD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—NOD2—leprosy	0.000555	0.0147	CbGpPWpGaD
Etoricoxib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000552	0.00469	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Thalidomide—leprosy	0.000549	0.00466	CcSEcCtD
Etoricoxib—Abdominal pain—Dapsone—leprosy	0.000548	0.00465	CcSEcCtD
Etoricoxib—Renal failure—Thalidomide—leprosy	0.000547	0.00465	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Thalidomide—leprosy	0.000546	0.00463	CcSEcCtD
Etoricoxib—Myocardial infarction—Thalidomide—leprosy	0.000546	0.00463	CcSEcCtD
Etoricoxib—Stomatitis—Thalidomide—leprosy	0.000542	0.00461	CcSEcCtD
Etoricoxib—Conjunctivitis—Thalidomide—leprosy	0.000541	0.00459	CcSEcCtD
Etoricoxib—Haematuria—Thalidomide—leprosy	0.000531	0.00451	CcSEcCtD
Etoricoxib—Epistaxis—Thalidomide—leprosy	0.000525	0.00446	CcSEcCtD
Etoricoxib—Sinusitis—Thalidomide—leprosy	0.000522	0.00443	CcSEcCtD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000507	0.0135	CbGpPWpGaD
Etoricoxib—Hepatitis—Thalidomide—leprosy	0.0005	0.00424	CcSEcCtD
Etoricoxib—Hypoaesthesia—Thalidomide—leprosy	0.000497	0.00422	CcSEcCtD
Etoricoxib—Pharyngitis—Thalidomide—leprosy	0.000496	0.00421	CcSEcCtD
Etoricoxib—Urinary tract disorder—Thalidomide—leprosy	0.000493	0.00419	CcSEcCtD
Etoricoxib—Oedema peripheral—Thalidomide—leprosy	0.000492	0.00418	CcSEcCtD
Etoricoxib—Urethral disorder—Thalidomide—leprosy	0.00049	0.00416	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000484	0.0129	CbGpPWpGaD
Etoricoxib—Visual impairment—Thalidomide—leprosy	0.000481	0.00409	CcSEcCtD
Etoricoxib—Erythema multiforme—Thalidomide—leprosy	0.000472	0.00401	CcSEcCtD
Etoricoxib—Eye disorder—Thalidomide—leprosy	0.000467	0.00397	CcSEcCtD
Etoricoxib—Tinnitus—Thalidomide—leprosy	0.000466	0.00396	CcSEcCtD
Etoricoxib—Cardiac disorder—Thalidomide—leprosy	0.000464	0.00394	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000459	0.0122	CbGpPWpGaD
Etoricoxib—Angiopathy—Thalidomide—leprosy	0.000453	0.00385	CcSEcCtD
Etoricoxib—Immune system disorder—Thalidomide—leprosy	0.000451	0.00383	CcSEcCtD
Etoricoxib—Mediastinal disorder—Thalidomide—leprosy	0.00045	0.00382	CcSEcCtD
Etoricoxib—Arrhythmia—Thalidomide—leprosy	0.000446	0.00379	CcSEcCtD
Etoricoxib—Alopecia—Thalidomide—leprosy	0.000441	0.00375	CcSEcCtD
Etoricoxib—Vomiting—Dapsone—leprosy	0.000441	0.00374	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000439	0.0117	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—CD8A—leprosy	0.000439	0.0117	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000438	0.0116	CbGpPWpGaD
Etoricoxib—Mental disorder—Thalidomide—leprosy	0.000438	0.00372	CcSEcCtD
Etoricoxib—Malnutrition—Thalidomide—leprosy	0.000435	0.00369	CcSEcCtD
Etoricoxib—Headache—Dapsone—leprosy	0.000434	0.00369	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000434	0.0115	CbGpPWpGaD
Etoricoxib—MAPK14—blood vessel—leprosy	0.000434	0.198	CbGeAlD
Etoricoxib—MAPK14—IL4-mediated signaling events—CD40LG—leprosy	0.000432	0.0115	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—IL10—leprosy	0.000432	0.0115	CbGpPWpGaD
Etoricoxib—Flatulence—Thalidomide—leprosy	0.000429	0.00364	CcSEcCtD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000426	0.0113	CbGpPWpGaD
Etoricoxib—Dysgeusia—Thalidomide—leprosy	0.000426	0.00362	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—RIPK2—leprosy	0.000419	0.0111	CbGpPWpGaD
Etoricoxib—Muscle spasms—Thalidomide—leprosy	0.000418	0.00355	CcSEcCtD
Etoricoxib—Nausea—Dapsone—leprosy	0.000412	0.0035	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000411	0.0109	CbGpPWpGaD
Etoricoxib—Vision blurred—Thalidomide—leprosy	0.00041	0.00348	CcSEcCtD
Etoricoxib—Tremor—Thalidomide—leprosy	0.000407	0.00346	CcSEcCtD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000404	0.0107	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000404	0.0107	CbGpPWpGaD
Etoricoxib—Anaemia—Thalidomide—leprosy	0.000402	0.00341	CcSEcCtD
Etoricoxib—Agitation—Thalidomide—leprosy	0.0004	0.00339	CcSEcCtD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000397	0.0106	CbGpPWpGaD
Etoricoxib—Angioedema—Thalidomide—leprosy	0.000397	0.00337	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000394	0.0105	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88-independent cascade—RIPK2—leprosy	0.000388	0.0103	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000387	0.0103	CbGpPWpGaD
Etoricoxib—Palpitations—Thalidomide—leprosy	0.000384	0.00326	CcSEcCtD
Etoricoxib—Cough—Thalidomide—leprosy	0.000379	0.00322	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000379	0.0101	CbGpPWpGaD
Etoricoxib—Hypertension—Thalidomide—leprosy	0.000375	0.00319	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000373	0.0099	CbGpPWpGaD
Etoricoxib—Arthralgia—Thalidomide—leprosy	0.00037	0.00314	CcSEcCtD
Etoricoxib—Chest pain—Thalidomide—leprosy	0.00037	0.00314	CcSEcCtD
Etoricoxib—Anxiety—Thalidomide—leprosy	0.000369	0.00313	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000368	0.00312	CcSEcCtD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000367	0.00973	CbGpPWpGaD
Etoricoxib—Dry mouth—Thalidomide—leprosy	0.000362	0.00308	CcSEcCtD
Etoricoxib—Confusional state—Thalidomide—leprosy	0.000358	0.00304	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—HLA-DRB1—leprosy	0.000357	0.00949	CbGpPWpGaD
Etoricoxib—Oedema—Thalidomide—leprosy	0.000355	0.00301	CcSEcCtD
Etoricoxib—Infection—Thalidomide—leprosy	0.000353	0.00299	CcSEcCtD
Etoricoxib—MAPK14—MyD88-independent cascade—NOD2—leprosy	0.000352	0.00934	CbGpPWpGaD
Etoricoxib—Shock—Thalidomide—leprosy	0.000349	0.00297	CcSEcCtD
Etoricoxib—MAPK14—Activated TLR4 signalling—RIPK2—leprosy	0.000349	0.00927	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—TLR2—leprosy	0.000349	0.00927	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Thalidomide—leprosy	0.000348	0.00296	CcSEcCtD
Etoricoxib—Thrombocytopenia—Thalidomide—leprosy	0.000348	0.00295	CcSEcCtD
Etoricoxib—Skin disorder—Thalidomide—leprosy	0.000345	0.00293	CcSEcCtD
Etoricoxib—Anorexia—Thalidomide—leprosy	0.000338	0.00287	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000328	0.00872	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000328	0.00872	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.000328	0.00871	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Thalidomide—leprosy	0.000323	0.00275	CcSEcCtD
Etoricoxib—Insomnia—Thalidomide—leprosy	0.000321	0.00273	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—CD8A—leprosy	0.000317	0.00843	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—NOD2—leprosy	0.000316	0.0084	CbGpPWpGaD
Etoricoxib—Dyspnoea—Thalidomide—leprosy	0.000316	0.00269	CcSEcCtD
Etoricoxib—Somnolence—Thalidomide—leprosy	0.000316	0.00268	CcSEcCtD
Etoricoxib—Dyspepsia—Thalidomide—leprosy	0.000312	0.00265	CcSEcCtD
Etoricoxib—Decreased appetite—Thalidomide—leprosy	0.000309	0.00262	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Thalidomide—leprosy	0.000306	0.0026	CcSEcCtD
Etoricoxib—Fatigue—Thalidomide—leprosy	0.000306	0.0026	CcSEcCtD
Etoricoxib—Pain—Thalidomide—leprosy	0.000304	0.00258	CcSEcCtD
Etoricoxib—Constipation—Thalidomide—leprosy	0.000304	0.00258	CcSEcCtD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000298	0.00792	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000298	0.0079	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000296	0.00785	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Thalidomide—leprosy	0.000292	0.00248	CcSEcCtD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—TLR2—leprosy	0.000292	0.00776	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000292	0.00776	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Thalidomide—leprosy	0.00029	0.00246	CcSEcCtD
Etoricoxib—MAPK14—IL2-mediated signaling events—IFNG—leprosy	0.000284	0.00754	CbGpPWpGaD
Etoricoxib—Urticaria—Thalidomide—leprosy	0.000282	0.00239	CcSEcCtD
Etoricoxib—Abdominal pain—Thalidomide—leprosy	0.000281	0.00238	CcSEcCtD
Etoricoxib—MAPK14—Monoamine Transport—TNF—leprosy	0.000279	0.00742	CbGpPWpGaD
Etoricoxib—PTGS2—Overview of nanoparticle effects—TNF—leprosy	0.000271	0.00719	CbGpPWpGaD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000265	0.00704	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—NOD2—leprosy	0.000265	0.00704	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IFNG—leprosy	0.000265	0.00702	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Thalidomide—leprosy	0.000261	0.00222	CcSEcCtD
Etoricoxib—PTGS2—hindlimb—leprosy	0.000261	0.119	CbGeAlD
Etoricoxib—MAPK14—IL12-mediated signaling events—IFNG—leprosy	0.000261	0.00693	CbGpPWpGaD
Etoricoxib—Asthenia—Thalidomide—leprosy	0.000255	0.00216	CcSEcCtD
Etoricoxib—MAPK14—IL2-mediated signaling events—IL2—leprosy	0.000252	0.0067	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—CD4—leprosy	0.000252	0.00669	CbGpPWpGaD
Etoricoxib—Pruritus—Thalidomide—leprosy	0.000251	0.00213	CcSEcCtD
Etoricoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—leprosy	0.000243	0.00646	CbGpPWpGaD
Etoricoxib—Diarrhoea—Thalidomide—leprosy	0.000243	0.00206	CcSEcCtD
Etoricoxib—Dizziness—Thalidomide—leprosy	0.000235	0.00199	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—IL2—leprosy	0.000232	0.00616	CbGpPWpGaD
Etoricoxib—Vomiting—Thalidomide—leprosy	0.000226	0.00192	CcSEcCtD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—TNF—leprosy	0.000225	0.00597	CbGpPWpGaD
Etoricoxib—PTGS2—appendage—leprosy	0.000224	0.102	CbGeAlD
Etoricoxib—Rash—Thalidomide—leprosy	0.000224	0.0019	CcSEcCtD
Etoricoxib—Dermatitis—Thalidomide—leprosy	0.000224	0.0019	CcSEcCtD
Etoricoxib—Headache—Thalidomide—leprosy	0.000222	0.00189	CcSEcCtD
Etoricoxib—Nausea—Thalidomide—leprosy	0.000211	0.00179	CcSEcCtD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.000203	0.0054	CbGpPWpGaD
Etoricoxib—MAPK14—skin of body—leprosy	0.000201	0.0916	CbGeAlD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000195	0.00519	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000193	0.00512	CbGpPWpGaD
Etoricoxib—PTGS2—skin epidermis—leprosy	0.000186	0.085	CbGeAlD
Etoricoxib—MAPK14—TCR Signaling Pathway—CD4—leprosy	0.000182	0.00484	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TNF—leprosy	0.000181	0.00481	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000181	0.0048	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.000171	0.00455	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000167	0.00443	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—RIPK2—leprosy	0.000166	0.00441	CbGpPWpGaD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—IL2—leprosy	0.000165	0.00437	CbGpPWpGaD
Etoricoxib—MAPK14—tendon—leprosy	0.000153	0.0697	CbGeAlD
Etoricoxib—MAPK14—Innate Immune System—CYLD—leprosy	0.000147	0.0039	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000133	0.00354	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000129	0.00343	CbGpPWpGaD
Etoricoxib—MAPK14—testis—leprosy	0.000127	0.0578	CbGeAlD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	0.000125	0.00332	CbGpPWpGaD
Etoricoxib—PTGS2—blood vessel—leprosy	0.000125	0.0569	CbGeAlD
Etoricoxib—MAPK14—nervous system—leprosy	0.000124	0.0567	CbGeAlD
Etoricoxib—PTGS2—C-MYB transcription factor network—CD4—leprosy	0.000123	0.00327	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	0.000123	0.00326	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000117	0.0031	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000111	0.00293	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000104	0.00275	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IFNG—leprosy	9.71e-05	0.00258	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—RIPK2—leprosy	9.47e-05	0.00251	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—TLR2—leprosy	9.47e-05	0.00251	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—leprosy	8.63e-05	0.00229	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL2—leprosy	8.63e-05	0.00229	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NOD2—leprosy	8.59e-05	0.00228	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CYLD—leprosy	8.56e-05	0.00227	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—IL2—leprosy	8.17e-05	0.00217	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—TNF—leprosy	7.94e-05	0.00211	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PARK2—leprosy	7.57e-05	0.00201	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	7.55e-05	0.00201	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	7.55e-05	0.00201	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TNF—leprosy	7.41e-05	0.00197	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.69e-05	0.00178	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNF—leprosy	6.28e-05	0.00167	CbGpPWpGaD
Etoricoxib—PTGS2—skin of body—leprosy	5.78e-05	0.0263	CbGeAlD
Etoricoxib—MAPK14—Immune System—RIPK2—leprosy	5.52e-05	0.00146	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TLR2—leprosy	5.52e-05	0.00146	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NOD2—leprosy	5e-05	0.00133	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SDHD—leprosy	4.97e-05	0.00132	CbGpPWpGaD
Etoricoxib—CYP2E1—tendon—leprosy	4.77e-05	0.0218	CbGeAlD
Etoricoxib—CYP2E1—Metabolism—SDHD—leprosy	4.68e-05	0.00124	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SLC11A1—leprosy	4.46e-05	0.00119	CbGpPWpGaD
Etoricoxib—PTGS2—tendon—leprosy	4.4e-05	0.0201	CbGeAlD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.27e-05	0.00113	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD40LG—leprosy	4.23e-05	0.00112	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—IL2—leprosy	4.21e-05	0.00112	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD8A—leprosy	4.18e-05	0.00111	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CD4—leprosy	4.12e-05	0.00109	CbGpPWpGaD
Etoricoxib—CYP2E1—testis—leprosy	3.95e-05	0.018	CbGeAlD
Etoricoxib—CYP2E1—nervous system—leprosy	3.88e-05	0.0177	CbGeAlD
Etoricoxib—CYP2C19—Metabolism—SDHD—leprosy	3.61e-05	0.000959	CbGpPWpGaD
Etoricoxib—PTGS2—nervous system—leprosy	3.57e-05	0.0163	CbGeAlD
Etoricoxib—MAPK14—Signaling Pathways—RIPK2—leprosy	3.57e-05	0.000947	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-DRB1—leprosy	3.4e-05	0.000904	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SDHD—leprosy	3.32e-05	0.000882	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SDHD—leprosy	3.29e-05	0.000874	CbGpPWpGaD
Etoricoxib—CYP2D6—testis—leprosy	3.13e-05	0.0143	CbGeAlD
Etoricoxib—MAPK14—Developmental Biology—TNF—leprosy	3.13e-05	0.000831	CbGpPWpGaD
Etoricoxib—CYP3A4—nervous system—leprosy	3.12e-05	0.0142	CbGeAlD
Etoricoxib—CYP2D6—nervous system—leprosy	3.07e-05	0.014	CbGeAlD
Etoricoxib—CYP1A2—Metabolism—SDHD—leprosy	2.81e-05	0.000747	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IFNG—leprosy	2.49e-05	0.00066	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD4—leprosy	2.4e-05	0.000637	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—leprosy	2.21e-05	0.000587	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SDHD—leprosy	2.17e-05	0.000577	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—leprosy	1.43e-05	0.000379	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD4—leprosy	1.42e-05	0.000376	CbGpPWpGaD
